Novartis partners with Canadian medical marijuana company Tilray

By zaymalz malz

Tilray, a Canadian medical marijuana company has signed a new deal with leading Swiss multinational pharmaceutical company Novartis to become the firm’s exclusive supplier of non-smokeable medical cannabis products for its Canadian subsidiary, Sandoz.

Tilray was the first medical cannabis firm to obtain a Good Manufacturing Practice certification (cGMP) in accordance with the standards of the European Medicine Agency. As a leader in the market, Tilray currently supplies tens of thousands of patients with its product across ten countries.

See also:

“This agreement is a major milestone on the long road to legitimizing medical cannabis as conventional medicine,” said Brendan Kennedy, Tilray’s Chief Executive Officer.

“Tilray is pleased to be, what we believe is, the first federally licensed producer of medical cannabis to form a strategic alliance with a local affiliate of a global pharmaceutical company to improve the availability and quality of medical cannabis products for Canadian patients in need.”

In addition to becoming the exclusive supplier of Sandoz, Tilray will also partner with the firm to develop new cannabis-based products that offer an alternative to smokable products that will then be distributed to Canadian hospitals and pharmacies.


Featured Articles

JPMorgan Chase: Committed to supporting the next generation

JPMorgan has unveiled a host of new and expanded philanthropic activities totalling US$3.5 million to support the development of apprenticeship programmes

How efficient digital ecosystems became business critical

During this unprecedented era of rapid digital transformation, establishing a well-functioning ecosystem stands to benefit both employees and customers

Mastercard: Supporting clients at a time of rapid evolution

Mastercard has announced a significant expansion of its consulting business with the launch of new practices dedicated to both AI and economics

Why Ceridian has boldly rebranded to Dayforce

Human Capital

McKinsey’s eight lessons in leadership for aspiring CEOs

Leadership & Strategy

KPMG: The biggest challenges facing global CEOs in 2023

Leadership & Strategy